CNS Penetration and Efficacy of Emerging Therapies

Panelists discuss how central nervous system (CNS) involvement in non–small cell lung cancer (NSCLC) poses ongoing challenges and how emerging therapies are addressing this need. They emphasize the value of agents with high CNS penetration and durable intracranial control, particularly newer tyrosine kinase inhibitors (TKIs) capable of crossing the blood-brain barrier. The discussion touches on updated NCCN guidelines recommending CNS-active options for patients with brain metastases, emphasizing how these agents improve both systemic and neurologic outcomes. This evolving understanding supports proactive CNS management as a key factor in treatment selection and patient survival.